View ValuationEuroapi 향후 성장Future 기준 점검 3/6Euroapi (는) 각각 연간 78.3% 및 2.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 82.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 1.1% 로 예상됩니다.핵심 정보78.3%이익 성장률82.13%EPS 성장률Pharmaceuticals 이익 성장10.4%매출 성장률2.5%향후 자기자본이익률1.14%애널리스트 커버리지Low마지막 업데이트12 May 2026최근 향후 성장 업데이트공시 • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.공시 • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.공시 • Oct 10Euroapi S.A. Provides Sales Guidance for the Full-Year 2023Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues.모든 업데이트 보기Recent updates공시 • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.공시 • Oct 02EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year.공시 • Jul 30+ 1 more updateEuroapi S.A. to Report Fiscal Year 2025 Results on Mar 03, 2026Euroapi S.A. announced that they will report fiscal year 2025 results on Mar 03, 2026공시 • Jul 02Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI).Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related to the company will be transferred to Particle Dynamics. The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements. Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025.공시 • Apr 17Euroapi S.A., Annual General Meeting, May 21, 2025Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris France공시 • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.공시 • Oct 16+ 1 more updateEUROAPI Announces CFO ChangesOlivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. Olivier Falut joins EUROAPI with close to 30 years of experience in management and finance in the industrial sector. Throughout his career, he held various financial positions in listed and non-listed companies, such as Fareva, Limagrain (including Vilmorin & Cie), Lactalis and Bel. Olivier Falut started his career in the financial audit sector, mainly at Ernst & Young in France and then in the United States. In 2001, he joined Bosch France as head of accounting and pursued his career as accounting director at Bel in 2003. In 2008, he joined Oberthur Technologies as CFO for the main business unit before moving to Lactalis (2012-2017) as head of group financial control. Since 2017, he has held CFO positions in various companies including Sodiaal, Segula Technologies, Limagrain and Fareva. Olivier Falut is a graduate from ESSEC business school and holds master’s degrees in business law. He also graduated from the French bar exam.공시 • Sep 13Euroapi S.A. to Report Fiscal Year 2024 Results on Mar 03, 2025Euroapi S.A. announced that they will report fiscal year 2024 results on Mar 03, 2025공시 • Jul 30+ 1 more updateEuroapi S.A. to Report First Half, 2025 Results on Jul 29, 2025Euroapi S.A. announced that they will report first half, 2025 results on Jul 29, 2025공시 • May 15+ 1 more updateEUROAPI Appoints Evelyne Nguyen as Chief Financial OfficerEvelyne Nguyen has been appointed EUROAPI’s Chief Financial Officer, effective May 14, 2024. She is taking over from Antoine Delcour, who is leaving the company to pursue new endeavors. Antoine will remain within the company until the end of June to ensure a smooth transition. Evelyne joins EUROAPI with over 30 years of experience in senior management and finance in the pharmaceutical and life science industries. Throughout her career, Eelyne held various finance, strategy, and management positions in listed and non-listed companies, such as Bristol Myers Squibb, SAUR, and LFB (Laboratoire Français du Fractionnement et des Biotechnologies). She has recently ssisted Biotech and Medtech companies with their strategic and financial projects. A graduate of ISG (Institut Supérieur de Gestion) and Stanford University Executive Program, Evelyne Nguyen started her career in Controlling and Finance for various international companies such as Coca-Cola and Schweppes. In 1987, she joined Bristol Myers Squibb France as a Business Planning and Financial Analysis Manager and pursued her career in Finance at SAUR (formerly Bouygues Group) in 1992. In 2007, she joined LFB, a biopharmaceutical company specialized in plasma derived medicinal products, and served during 12 years as CFO-Executive Vice President Finance and Strategy, supervising Strategic Planning, M&A, Corporate Finance, Internal Audit, and Information Systems. As a member of the Executive Committee, she was appointed Executive Vice President of Development and Biomanufacturing in 2010, in charge, notably, of CDMO business development, manufacturing scale up and strategic alliances. Evelyne has international experience with Europe, US and Asia. Since 2013, Evelyne Nguyen has worked as Finance, Strategy, and Business Development Advisor, supporting healthcare companies in several areas, including IPOs, debt and fund raising, strategic roadmap, business plan, and M&A.공시 • Apr 10Euroapi S.A. Announces Executive and Executive Committee ChangesEUROAPI announced a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other opportunities outside of the company. The new Executive Committee will be composed of: Antoine Delcour,Chief Financial Officer, Thierry Durand,Chief R&D Officer, Ute Herzog, Chief Human Resources Officer, Cécile Maupas, Chief CDMO Officer, Guillaume Rosso, Chief Commercial Officer, David Seignolle, Chief Operating Officer.New Risk • Mar 06New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -€128m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Less than 1 year of cash runway based on current free cash flow (-€128m).Board Change • Mar 06High number of new and inexperienced directorsThere are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Nominating Director Adeline Franc is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Nov 29EUROAPI Announces Executive ChangesEUROAPI announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innovation and product development to support the company's ambition. He will actively oversee the industrial execution of the strategic review announced on October 9, 2023. David Seignolle, a French citizen, joins EUROAPI from Bain & Company where he served as Expert Partner in the Healthcare Practice. Prior to this, David spent 6 years at TEVA where he held several positions such as Head of Operations for Teva API in Italy and Mexico, Vice President Global Supply Chain API and Biologics or Site General Manager. David has also served 5 years at McKinsey & Company in France and in the US where he was focusing on Pharma Operations after beginning his career in Procurement at Toyota Motor Europe. David has a degree in Mechanical Engineering & Industrial Science as well as a postmaster degree in International Procurement Management. Marion Santin, a French citizen, began her career as an associate in law firms, first at Kramer Levin Naftalis & Frankel LLP and then at DLA Piper. She then joined Sanofi in 2006, where she first held the position of Industrial Affairs Legal Manager, then Alliances & Partnerships Legal Director, Mergers & Acquisitions Legal Director before becoming Commercial Operations Legal Director for the legal teams based in Asia, the Middle East, India, Hong Kong and Taiwan. Marion holds an Advanced Degree in Business Law and a Magistère in Business Law from the University of Paris I - Panthéon-Sorbonne. Marion is also a member of the Paris Bar.공시 • Nov 22Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh on November 21, 2023. As planned, Biano will retain its corporate brand and become a EUROAPI company.공시 • Oct 26+ 1 more updateEuroapi S.A. Announces Executive Changes, Effective October 30, 2023EUROAPI S.A’s Board of Directors met on October 25, 2023, and decided that Karl Rotthier will step down as Chief Executive Officer, effective October 30, 2023. The Board has launched a search for a new Chief Executive Officer. Consequently, it has appointed Viviane Monges, EUROAPI’s current Chair of the Board, as Chief Executive Officer until a permanent successor has been appointed. She will remain EUROAPI’s Chair of the Board. Viviane Monges is an experienced Finance Executive and Director and has worked in several business sectors and more than 25 years in the pharmaceutical industry. She served as Chief Financial Officer of the group Galderma S.A., a multinational company specializing in dermatology. She was Chief Financial Officer of the EMEA region and then World Chief Financial Officer for the OTC division at Novartis. At Wyeth Pharmaceuticals/Pfizer, sheheld the position of Chief Financial Officer of the Global Pharma Business unit. She served on several Pharma companies' boards and is currently a member of the Board of Novo Holdings, Ferring Pharmaceuticals and Pharvaris.Valuation Update With 7 Day Price Move • Oct 11Investor sentiment deteriorates as stock falls 53%After last week's 53% share price decline to €5.53, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 15x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 69% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €9.63 per share.공시 • Oct 10Euroapi S.A. Provides Sales Guidance for the Full-Year 2023Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues.공시 • Aug 31Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Reported Earnings • Aug 02First half 2023 earnings released: EPS: €0.67 (vs €0.18 in 1H 2022)First half 2023 results: EPS: €0.67 (up from €0.18 in 1H 2022). Revenue: €498.5m (up 2.6% from 1H 2022). Net income: €62.8m (up 276% from 1H 2022). Profit margin: 13% (up from 3.4% in 1H 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.공시 • Aug 01+ 2 more updatesEuroapi S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024Euroapi S.A. announced that they will report fiscal year 2023 results Pre-Market on Feb 29, 2024Reported Earnings • Mar 10Full year 2022 earnings releasedFull year 2022 results: Revenue: €980.9m (up 9.9% from FY 2021). Net loss: €15.0m (loss narrowed 5.1% from FY 2021). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom.공시 • Jan 12EUROAPI Announces Resignation of Corinne Le Goff as an Independent Member on the Board of DirectorsThe board of directors of EUROAPI announced Corinne Le Goff, after serving as an independent member on the board of directors since May 6, 2022, has resigned from her directorship as of January 11, 2023.Buying Opportunity • Dec 08Now 29% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be €20.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings is also forecast to grow by 32% per annum over the same time period.Buying Opportunity • Nov 17Now 20% undervaluedOver the last 90 days, the stock is up 9.1%. The fair value is estimated to be €21.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings is also forecast to grow by 31% per annum over the same time period.공시 • Sep 01Euroapi S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023Euroapi S.A. announced that they will report fiscal year 2022 results Pre-Market on Mar 08, 2023이익 및 매출 성장 예측BATS-CHIXE:EAPIP - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202883711989412/31/2027804-403062512/31/2026760-767592412/31/2025853-21150129N/A9/30/2025868-1681899N/A6/30/2025883-124-1470N/A3/31/2025901-127097N/A12/31/2024919-13115123N/A9/30/2024945-2094119N/A6/30/2024971-287-6115N/A3/31/2024995-238-6760N/A12/31/20231,019-190-1285N/A9/30/20231,006-79-1164N/A6/30/202399431-1053N/A3/31/20239878-8724N/A12/31/2022981-15-6945N/A9/30/2022962-3-9946N/A6/30/202294410-12947N/A3/31/20229181-9659N/A12/31/2021893-8-6472N/A12/31/2020945-6897N/A12/31/20199163-4735N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: EAPIP 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.4%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: EAPIP (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: EAPIP 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: EAPIP 의 수익(연간 2.5%)이 UK 시장(연간 4.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: EAPIP 의 수익(연간 2.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: EAPIP의 자본 수익률은 3년 후 1.1%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 22:22종가2026/03/19 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Euroapi S.A.는 11명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Justin Steven SmithBernsteinPatrick Andrew WoodBofA Global ResearchFynn ScherzlerDeutsche Bank8명의 분석가 더 보기
공시 • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.
공시 • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.
공시 • Oct 10Euroapi S.A. Provides Sales Guidance for the Full-Year 2023Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues.
공시 • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.
공시 • Oct 02EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year.
공시 • Jul 30+ 1 more updateEuroapi S.A. to Report Fiscal Year 2025 Results on Mar 03, 2026Euroapi S.A. announced that they will report fiscal year 2025 results on Mar 03, 2026
공시 • Jul 02Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI).Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related to the company will be transferred to Particle Dynamics. The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements. Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025.
공시 • Apr 17Euroapi S.A., Annual General Meeting, May 21, 2025Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris France
공시 • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.
공시 • Oct 16+ 1 more updateEUROAPI Announces CFO ChangesOlivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. Olivier Falut joins EUROAPI with close to 30 years of experience in management and finance in the industrial sector. Throughout his career, he held various financial positions in listed and non-listed companies, such as Fareva, Limagrain (including Vilmorin & Cie), Lactalis and Bel. Olivier Falut started his career in the financial audit sector, mainly at Ernst & Young in France and then in the United States. In 2001, he joined Bosch France as head of accounting and pursued his career as accounting director at Bel in 2003. In 2008, he joined Oberthur Technologies as CFO for the main business unit before moving to Lactalis (2012-2017) as head of group financial control. Since 2017, he has held CFO positions in various companies including Sodiaal, Segula Technologies, Limagrain and Fareva. Olivier Falut is a graduate from ESSEC business school and holds master’s degrees in business law. He also graduated from the French bar exam.
공시 • Sep 13Euroapi S.A. to Report Fiscal Year 2024 Results on Mar 03, 2025Euroapi S.A. announced that they will report fiscal year 2024 results on Mar 03, 2025
공시 • Jul 30+ 1 more updateEuroapi S.A. to Report First Half, 2025 Results on Jul 29, 2025Euroapi S.A. announced that they will report first half, 2025 results on Jul 29, 2025
공시 • May 15+ 1 more updateEUROAPI Appoints Evelyne Nguyen as Chief Financial OfficerEvelyne Nguyen has been appointed EUROAPI’s Chief Financial Officer, effective May 14, 2024. She is taking over from Antoine Delcour, who is leaving the company to pursue new endeavors. Antoine will remain within the company until the end of June to ensure a smooth transition. Evelyne joins EUROAPI with over 30 years of experience in senior management and finance in the pharmaceutical and life science industries. Throughout her career, Eelyne held various finance, strategy, and management positions in listed and non-listed companies, such as Bristol Myers Squibb, SAUR, and LFB (Laboratoire Français du Fractionnement et des Biotechnologies). She has recently ssisted Biotech and Medtech companies with their strategic and financial projects. A graduate of ISG (Institut Supérieur de Gestion) and Stanford University Executive Program, Evelyne Nguyen started her career in Controlling and Finance for various international companies such as Coca-Cola and Schweppes. In 1987, she joined Bristol Myers Squibb France as a Business Planning and Financial Analysis Manager and pursued her career in Finance at SAUR (formerly Bouygues Group) in 1992. In 2007, she joined LFB, a biopharmaceutical company specialized in plasma derived medicinal products, and served during 12 years as CFO-Executive Vice President Finance and Strategy, supervising Strategic Planning, M&A, Corporate Finance, Internal Audit, and Information Systems. As a member of the Executive Committee, she was appointed Executive Vice President of Development and Biomanufacturing in 2010, in charge, notably, of CDMO business development, manufacturing scale up and strategic alliances. Evelyne has international experience with Europe, US and Asia. Since 2013, Evelyne Nguyen has worked as Finance, Strategy, and Business Development Advisor, supporting healthcare companies in several areas, including IPOs, debt and fund raising, strategic roadmap, business plan, and M&A.
공시 • Apr 10Euroapi S.A. Announces Executive and Executive Committee ChangesEUROAPI announced a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other opportunities outside of the company. The new Executive Committee will be composed of: Antoine Delcour,Chief Financial Officer, Thierry Durand,Chief R&D Officer, Ute Herzog, Chief Human Resources Officer, Cécile Maupas, Chief CDMO Officer, Guillaume Rosso, Chief Commercial Officer, David Seignolle, Chief Operating Officer.
New Risk • Mar 06New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -€128m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Less than 1 year of cash runway based on current free cash flow (-€128m).
Board Change • Mar 06High number of new and inexperienced directorsThere are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Nominating Director Adeline Franc is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Nov 29EUROAPI Announces Executive ChangesEUROAPI announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innovation and product development to support the company's ambition. He will actively oversee the industrial execution of the strategic review announced on October 9, 2023. David Seignolle, a French citizen, joins EUROAPI from Bain & Company where he served as Expert Partner in the Healthcare Practice. Prior to this, David spent 6 years at TEVA where he held several positions such as Head of Operations for Teva API in Italy and Mexico, Vice President Global Supply Chain API and Biologics or Site General Manager. David has also served 5 years at McKinsey & Company in France and in the US where he was focusing on Pharma Operations after beginning his career in Procurement at Toyota Motor Europe. David has a degree in Mechanical Engineering & Industrial Science as well as a postmaster degree in International Procurement Management. Marion Santin, a French citizen, began her career as an associate in law firms, first at Kramer Levin Naftalis & Frankel LLP and then at DLA Piper. She then joined Sanofi in 2006, where she first held the position of Industrial Affairs Legal Manager, then Alliances & Partnerships Legal Director, Mergers & Acquisitions Legal Director before becoming Commercial Operations Legal Director for the legal teams based in Asia, the Middle East, India, Hong Kong and Taiwan. Marion holds an Advanced Degree in Business Law and a Magistère in Business Law from the University of Paris I - Panthéon-Sorbonne. Marion is also a member of the Paris Bar.
공시 • Nov 22Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh on November 21, 2023. As planned, Biano will retain its corporate brand and become a EUROAPI company.
공시 • Oct 26+ 1 more updateEuroapi S.A. Announces Executive Changes, Effective October 30, 2023EUROAPI S.A’s Board of Directors met on October 25, 2023, and decided that Karl Rotthier will step down as Chief Executive Officer, effective October 30, 2023. The Board has launched a search for a new Chief Executive Officer. Consequently, it has appointed Viviane Monges, EUROAPI’s current Chair of the Board, as Chief Executive Officer until a permanent successor has been appointed. She will remain EUROAPI’s Chair of the Board. Viviane Monges is an experienced Finance Executive and Director and has worked in several business sectors and more than 25 years in the pharmaceutical industry. She served as Chief Financial Officer of the group Galderma S.A., a multinational company specializing in dermatology. She was Chief Financial Officer of the EMEA region and then World Chief Financial Officer for the OTC division at Novartis. At Wyeth Pharmaceuticals/Pfizer, sheheld the position of Chief Financial Officer of the Global Pharma Business unit. She served on several Pharma companies' boards and is currently a member of the Board of Novo Holdings, Ferring Pharmaceuticals and Pharvaris.
Valuation Update With 7 Day Price Move • Oct 11Investor sentiment deteriorates as stock falls 53%After last week's 53% share price decline to €5.53, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 15x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 69% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €9.63 per share.
공시 • Oct 10Euroapi S.A. Provides Sales Guidance for the Full-Year 2023Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues.
공시 • Aug 31Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.
Reported Earnings • Aug 02First half 2023 earnings released: EPS: €0.67 (vs €0.18 in 1H 2022)First half 2023 results: EPS: €0.67 (up from €0.18 in 1H 2022). Revenue: €498.5m (up 2.6% from 1H 2022). Net income: €62.8m (up 276% from 1H 2022). Profit margin: 13% (up from 3.4% in 1H 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.
공시 • Aug 01+ 2 more updatesEuroapi S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024Euroapi S.A. announced that they will report fiscal year 2023 results Pre-Market on Feb 29, 2024
Reported Earnings • Mar 10Full year 2022 earnings releasedFull year 2022 results: Revenue: €980.9m (up 9.9% from FY 2021). Net loss: €15.0m (loss narrowed 5.1% from FY 2021). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom.
공시 • Jan 12EUROAPI Announces Resignation of Corinne Le Goff as an Independent Member on the Board of DirectorsThe board of directors of EUROAPI announced Corinne Le Goff, after serving as an independent member on the board of directors since May 6, 2022, has resigned from her directorship as of January 11, 2023.
Buying Opportunity • Dec 08Now 29% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be €20.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings is also forecast to grow by 32% per annum over the same time period.
Buying Opportunity • Nov 17Now 20% undervaluedOver the last 90 days, the stock is up 9.1%. The fair value is estimated to be €21.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings is also forecast to grow by 31% per annum over the same time period.
공시 • Sep 01Euroapi S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023Euroapi S.A. announced that they will report fiscal year 2022 results Pre-Market on Mar 08, 2023